RxDoctor Payments Data

Benjamin Chadi, MD

Cardiovascular Disease · Ny, NYNPI 1487742748

Payments from drug & device makers

$250in general payments, 2019–2025

Across 9 payments — averaging $27.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$66
  • Merck$43
  • Philips North America LLC$33
  • Bridgebio Pharma, Inc.$31
  • Sanofi-aventis U.S. LLC$29
  • Pfizer$26
  • plus $22 from 1 others

What the payments were for

  • Food & beverage$250100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$250 in reported general payments places this provider in the 15th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$59,192
Medicare patients
94
Services billed
414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$43,838
Diclofenac Sodium21$1,582
Atorvastatin Calcium106$737
Metoprolol Succinate44$585
Amlodipine Besylate82$564
Venlafaxine Hcl ErVenlafaxine Hcl13$535
Nifedipine ErNifedipine11$453
Rosuvastatin Calcium29$399
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid36$327
Zolpidem Tartrate ErZolpidem Tartrate12$288
Tamsulosin Hcl13$235
Metformin Hcl18$186
Lisinopril31$159
Amiodarone Hcl16$147
Hydralazine Hcl16$144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$43,83873 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Ny

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →